Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Shenzhen Sanzhi Medical Technology Co., Ltd., established on 2017-04-17, Business scope includes general business items:Agricultural Technology,Biotechnology,new material technology,Promotion of Energy Saving Technology;Technical development of biological products;Technology development of biotechnology products;Science and Technology Information Consulting;Scientific research and technical service industry;Basic medical research and development,clinical research and development,Pharmaceutical R&D,Research and development of new anti-tumor drugs and technologies,Clinical research and development of new anti-tumor drugs and technologies,Small molecule drug synthesis research and development,Clinical biomarker development,Genetic Sequencing for Drug Evaluation Development,Research and development combining basic drug research and clinical medical research,Development of small molecule formulations,The licensing program is:

IXYS Corporation a Silicon Valley power semiconductor company, has been developing technology-driven products to improve power conversion efficiency. IXYS is a pioneer in the development of power semiconductors that effectively monitor electrical voltage to produce maximum effect with least expenditure of energy. Through its nine divisions, IXYS offers products and technologies that span the entire power spectrum, addressing more than 90% of the overall power market.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Shanghai Dayao Biotechnology Co., Ltd., established on 2015-07-07, The scope of business includes engaging in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,e-commerce(Not allowed to engage in value-added telecommunications,Financial services),daily necessities,cosmetic,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)promotion of,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]